Please assess the completion status of the following clinical trial:

Trial Title: Predictive Factors Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Acromegaly.~* Males and females aged 18 years and older.~* Signed informed consent (patient must give consent to the collection of retrospective data).~* Patients who have had surgery may enter the study 3 months post-surgery and evaluated for the duration of the study.~* With the intention to be treated with ATG (decision to prescribe ATG made prior to inclusion into the study) or already being treated with ATG.~* If already being treated with ATG:~Previous ATG treatment maximum of 3 months. AND Minimum data available (demographic data, disease history including previous treatments, GH, IGF-1 levels at baseline and under treatment as applicable).~* Not receiving Dopamine Agonists or other medical therapy (Pegvisomant, or other somatostatin analogues) for the treatment or symptom control of acromegaly.~Exclusion Criteria:~* The subject has had radiotherapy in the last 5 years.~* The subject has had surgery in the last 3 months.~* The subject has already been included in this study.~* Participation in an interventional trial, or receiving experimental drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acromegalic patients (Type: None): Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)

Based on this trial design, predict the completion outcome and termination type (if applicable).